Immunotherapy comes of age: Immune aging & checkpoint inhibitors

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · see citing works

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · see citing works

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · see citing works

PD-1 and Its Ligands in Tolerance and Immunity

Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · see citing works

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · see citing works

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · see citing works

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101 · see citing works

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025 · see citing works

The immune contexture in human tumours: impact on clinical outcome

Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981 · see citing works

Restoring function in exhausted CD8 T cells during chronic viral infection

Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 3,960 · see citing works

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · see citing works

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,564 · see citing works

Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,259 · see citing works

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756 · see citing works

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157 · see citing works

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

Deng, L., Liang, H. L., Burnette, B., Beckett, M., Darga, T. E., Weichselbaum, R. R., & Fu, Y. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,101 · see citing works

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,072 · see citing works

Up-Regulation of PD-L1, IDO, and T _regs in the Melanoma Tumor Microenvironment Is Driven by CD8 ⁺ T Cells

Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677 · see citing works

Inhibitory B7-family molecules in the tumour microenvironment

Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608 · see citing works

Immunological effects of conventional chemotherapy and targeted anticancer agents

Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530 · see citing works

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487 · see citing works

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472 · see citing works

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2006) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,341 · see citing works

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity

Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · see citing works

Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.

Bates, G. J., Fox, S., Han, C., Leek, R., García, J. F., Harris, A., & Banham, A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9584 · Cited by 1,209 · see citing works

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Champiat, S., Dercle, L., Ammari, S., Massard, C., Hollebecque, A., Postel-Vinay, S. C., Chaput, N., Eggermont, A. M. M., Marabelle, A., Soria, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1741 · Cited by 1,188 · see citing works

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,176 · see citing works

Foxp3-dependent programme of regulatory T-cell differentiation

Gavin, M. A., Rasmussen, J. P., Fontenot, J. D., Vasta, V., Manganiello, V. C., Beavo, J. A., & Rudensky, A. Y. (2007) · Nature · doi:10.1038/nature05543 · Cited by 1,127 · see citing works

Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age

Rossi, D. J., Bryder, D., Seita, J., Nussenzweig, A., Hoeijmakers, J., & Weissman, I. L. (2007) · Nature · doi:10.1038/nature05862 · Cited by 1,115 · see citing works

Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma

Rosenwald, A., Wright, G. W., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R. D., Chan, W. C., Zhao, T., Haïoun, C., Greiner, T. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031074 · Cited by 1,095 · see citing works

Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells

Brenchley, J. M., Karandikar, N. J., Betts, M. R., Ambrozak, D. R., Hill, B. J., Crotty, L. E., Casazza, J. P., Kuruppu, J., Migueles, S. A., Connors, M., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2103 · Cited by 1,073 · see citing works

Regulatory T cells in tumor immunity

Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944 · see citing works

Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells

Zheng, Y., Josefowicz, S. Z., Kas, A., Chu, T.-T., Gavin, M. A., & Rudensky, A. Y. (2007) · Nature · doi:10.1038/nature05563 · Cited by 835 · see citing works

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

Benson, D. M., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A., Zhang, J., Yu, J., Smith, M. K., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271874 · Cited by 807 · see citing works

The Influence of Age on T Cell Generation and TCR Diversity

Naylor, K., Li, G., Vallejo, A. N., Lee, W.-W., Koetz, K., Bryl, E., Witkowski, J., Fulbright, J., Weyand, C. M., & Goronzy, J. J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.7446 · Cited by 802 · see citing works

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses

Walker, L. S. K., & Sansom, D. M. (2011) · Nature reviews. Immunology · doi:10.1038/nri3108 · Cited by 786 · see citing works

PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772 · see citing works

Enhancing SIV-specific immunity in vivo by PD-1 blockade

Velu, V., Titanji, K., Zhu, B., Husain, S., Pladevega, A., Lai, L., Vanderford, T. H., Chennareddi, L. S., Silvestri, G., Freeman, G. J., et al. (2008) · Nature · doi:10.1038/nature07662 · Cited by 765 · see citing works

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M. E., Wang, H. Y., Wysocka, M., Cheng, M. M., Ruggeri, B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810958105 · Cited by 731 · see citing works

CD28− T cells: their role in the age-associated decline of immune function

Weng, N., Akbar, A. N., & Goronzy, J. J. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.03.013 · Cited by 629 · see citing works

The ageing haematopoietic stem cell compartment

Geiger, H., de Haan, G., & Florian, M. C. (2013) · Nature Reviews Immunology · doi:10.1038/nri3433 · Cited by 604 · see citing works

Innate Immune Recognition of Cancer

Woo, S., Corrales, L. P., & Gajewski, T. F. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112043 · Cited by 569 · see citing works

Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response

Panda, A., Qian, F., Mohanty, S., van Duin, D., Newman, F. K., Zhang, L., Chen, S., Towle, V., Belshe, R. B., Fikrig, E., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901022 · Cited by 548 · see citing works

Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomão, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm0902-1039c · Cited by 545 · see citing works

CD4 + CD25 + regulatory T cells in patients with gastrointestinal malignancies

Sasada, T., Kimura, M., Yoshida, Y., Kanai, M., & Takabayashi, A. (2003) · Cancer · doi:10.1002/cncr.11618 · Cited by 485 · see citing works

T cell subset-specific susceptibility to aging

Czesnikiewicz-Guzik, M., Lee, W.-W., Cui, D., Hiruma, Y., Lamar, D. L., Yang, Z.-Z., Ouslander, J. G., Weyand, C. M., & Goronzy, J. J. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.12.002 · Cited by 478 · see citing works

Tumor infiltrating Foxp3+ regulatory T‐cells are associated with recurrence in pathologic stage I NSCLC patients

Petersen, R., Campa, M. J., Sperlazza, J., Conlon, D. H., Joshi, M., Harpole, D., & Patz, E. (2006) · Cancer · doi:10.1002/cncr.22282 · Cited by 471 · see citing works

Lymphostromal interactions in thymic development and function

Anderson, G., & Jenkinson, E. J. (2001) · Nature reviews. Immunology · doi:10.1038/35095500 · Cited by 461 · see citing works

Lymphoproliferation in CTLA-4–Deficient Mice Is Mediated by Costimulation-Dependent Activation of CD4 + T Cells

Chambers, C. A., Sullivan, T. J., & Allison, J. P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80406-9 · Cited by 411 · see citing works

The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age

Gregg, R., Smith, C. M., Clark, F. J., Dunnion, D., Khan, N., Chakraverty, R. K., Nayak, L., & Moss, P. A. H. (2005) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2005.02798.x · Cited by 377 · see citing works

IL-18 Induces PD-1–Dependent Immunosuppression in Cancer

Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Desbois, M., Delahaye, N., Viaud, S., Ryffel, B., Yagita, H., Kaplanski, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0993 · Cited by 376 · see citing works

Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people

Koch, S. D., Larbi, A., Derhovanessian, E., Özcelik, D., Naumova, E. J., & Pawelec, G. (2008) · Immunity & Ageing · doi:10.1186/1742-4933-5-6 · Cited by 360 · see citing works

Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T cell subsets in humans

Wertheimer, A. M., Bennett, M. S., Park, B., Uhrlaub, J. L., Martinez, C., Pulko, V., Currier, N. L., Nikolich-Žugich, D., Kaye, J., & Nikolich-Žugich, J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301721 · Cited by 352 · see citing works

Naive T Cell Maintenance and Function in Human Aging

Goronzy, J. J., Fang, F., Cavanagh, M., Qi, Q., & Weyand, C. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500046 · Cited by 348 · see citing works

The aging innate immune system

Gómez, C. R., Boehmer, E. D., & Kovacs, E. J. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.07.013 · Cited by 317 · see citing works

Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis

Nishijima, T. F., Muss, H. B., Shachar, S. S., & Moschos, S. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.006 · Cited by 293 · see citing works

Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood

Jing, Y., Shaheen, E., Drake, R. R., Chen, N., Gravenstein, S., & Deng, Y. (2009) · Human Immunology · doi:10.1016/j.humimm.2009.07.005 · Cited by 284 · see citing works

Aging and T-cell diversity☆

Goronzy, J. J., Lee, W., & Weyand, C. M. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2006.11.016 · Cited by 267 · see citing works

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

Kavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J. P., Small, E. J., & Fong, L. (2008) · Blood · doi:10.1182/blood-2007-11-125435 · Cited by 256 · see citing works

Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice

Kelly, J., Khan, A. A., Yin, J., Ferguson, T. A., & Apte, R. S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32430 · Cited by 249 · see citing works

Blood CD33(+)HLA-DR(−) myeloid-derived suppressor cells are increased with age and a history of cancer

Verschoor, C. P., Johnstone, J., Millar, J., Dorrington, M. G., Habibagahi, M., Lelic, A., Loeb, M., Bramson, J. L., & Bowdish, D. M. E. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0912461 · Cited by 235 · see citing works

Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy

Peggs, K. S., Quezada, S. A., & Allison, J. P. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00649.x · Cited by 228 · see citing works

Myeloid-Derived Suppressor Cells in Human Cancer

Nagaraj, S., & Gabrilovich, D. I. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb3358 · Cited by 222 · see citing works

Advanced Age Impairs Macrophage Polarization

Mahbub, S., Deburghgraeve, C. R., & Kovacs, E. J. (2012) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2011.0058 · Cited by 222 · see citing works

The molecular pathogenesis of primary mediastinal large B-cell lymphoma

Steidl, C., & Gascoyne, R. D. (2011) · Blood · doi:10.1182/blood-2011-05-326538 · Cited by 206 · see citing works

Thymus Size and Age-related Thymic Involution: Early Programming, Sexual Dimorphism, Progenitors and Stroma.

Gui, J., Mustachio, L. M., Su, D., & Craig, R. W. (2012) · Europe PMC (PubMed Central) · Cited by 200 · see citing works

Reciprocal Relationship between Myeloid-Derived Suppressor Cells and T Cells

Nagaraj, S., Youn, J., & Gabrilovich, D. I. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300654 · Cited by 179 · see citing works

Clonality and longevity of CD4+CD28null T cells are associated with defects in apoptotic pathways

Vallejo, A. N., Schirmer, M., Weyand, C. M., & Goronzy, J. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6301 · Cited by 169 · see citing works

Age-associated impaired plasmacytoid dendritic cell functions lead to decreased CD4 and CD8 T cell immunity

Sridharan, A., Esposo, M., Kaushal, K., Tay, J., Osann, K., Agrawal, S., Gupta, S., & Agrawal, A. (2011) · AGE · doi:10.1007/s11357-010-9191-3 · Cited by 165 · see citing works

Homeostasis and function of regulatory T cells in aging

Raynor, J. L., Lages, C. S., Shehata, H. M., Hildeman, D. A., & Chougnet, C. A. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.04.005 · Cited by 164 · see citing works

Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28− T cells and inhibit both T-Cell proliferation and CTL function

Filaci, G., Fravega, M., Negrini, S., Procopio, F., Fenoglio, D., Rizzi, M., Brenci, S., Contini, P., Olive, D., Ghio, M., et al. (2004) · Human Immunology · doi:10.1016/j.humimm.2003.12.001 · Cited by 163 · see citing works

CD4+CD25+ T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans—impact of immunosenescence

Trzonkowski, P., Szmit, E., Myśliwska, J. M., & Myśliwski, A. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.02.002 · Cited by 152 · see citing works

Impaired Dendritic Cell Function in Aging Leads to Defective Antitumor Immunity

Grolleau‐Julius, A., Harning, E. K., Close, L. A., & Yung, R. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5769 · Cited by 151 · see citing works

Impaired Interferon Signaling in Dendritic Cells From Older Donors Infected In Vitro With West Nile Virus

Qian, F., Wang, X., Zhang, L., Lin, A., Zhao, H., Fikrig, E., & Montgomery, R. R. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir048 · Cited by 151 · see citing works

Blockade of PD‐1 or p38 MAP kinase signaling enhances senescent human CD8⁺ T‐cell proliferation by distinct pathways

Henson, S. M., Macaulay, R., Riddell, N. E., Nunn, C. J., & Akbar, A. N. (2015) · European Journal of Immunology · doi:10.1002/eji.201445312 · Cited by 146 · see citing works

Partial restoration of T‐cell function in aged mice by in vitro blockade of the PD‐1/ PD‐L1 pathway

Lages, C. S., Lewkowich, I. P., Sproles, A. A., Wills-Karp, M. A., & Chougnet, C. A. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2010.00611.x · Cited by 140 · see citing works

Aging disturbs the balance between effector and regulatory CD4+ T cells

van der Geest, K. S. M., Abdulahad, W. H., Tete, S. M., Lorencetti, P. G., Horst, G., Bos, N. A., Kroesen, B., Brouwer, E., & Boots, A. M. H. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.11.005 · Cited by 131 · see citing works

Ontogeny and Polarization of Macrophages in Inflammation: Blood Monocytes Versus Tissue Macrophages

Dey, A., Allen, J., & Hankey-Giblin, P. A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00683 · Cited by 126 · see citing works

Age-associated alterations in the recruitment of signal-transduction proteins to lipid rafts in human T lymphocytes

Larbi, A., Douziech, N., Dupuis, G., Khalil, A., Pelletier, H., Guérard, K., & Fülöp, T. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0703319 · Cited by 126 · see citing works

Persistence of Tumor Infiltrating Lymphocytes in Adoptive Immunotherapy Correlates With Telomere Length

Shen, X., Zhou, J., Hathcock, K. S., Robbins, P. F., Powell, D. J., Rosenberg, S. A., & Hodes, R. J. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211321.07654.b8 · Cited by 122 · see citing works

Dendritic cells in human aging

AGRAWAL, A., Agrawal, S., & Gupta, S. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2006.11.007 · Cited by 122 · see citing works

The role of CD4 T cell help for CD8 CTL activation

Zhang, S., Zhang, H., & Zhao, J. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.04.134 · Cited by 118 · see citing works

Naïve T Cells in the Elderly

Pfister, G., Weiskopf, D., Lazuardi, L., Kovaiou, R. D., Cioca, D., Keller, M., LORBEG, B., Parson, W., & Grubeck‐Loebenstein, B. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1354.018 · Cited by 118 · see citing works

The characterization of varicella zoster virus-specific T cells in skin and blood during aging

Vukmanovic-Stejic, M., Sandhu, D., Seidel, J. A., Patel, N., Sobande, T. O., Agius, E., Jackson, S. E., Fuentes-Duculan, J., Suárez-Fariñas, M., Mabbott, N. A., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.63 · Cited by 117 · see citing works

New monoclonal antibodies against B-cell antigens: Possible new strategies for diagnosis of primary cutaneous B-cell lymphomas

Fanoni, D., Tavecchio, S., Recalcati, S., Balice, Y., Venegoni, L., Fiorani, R., CROSTI, C., & Berti, E. (2010) · Immunology Letters · doi:10.1016/j.imlet.2010.09.022 · Cited by 115 · see citing works

Age-related deregulation of naive T cell homeostasis in elderly humans

Ferrando‐Martínez, S., Ruíz-Mateos, E., Hernández, A., Gutiérrez, E., Rodríguez-Méndez, M. M., Ordóñez, A., & Leal, M. (2010) · AGE · doi:10.1007/s11357-010-9170-8 · Cited by 109 · see citing works

B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer

Liu, Y., Zeng, B., Zhang, Z., Zhang, Y. C., & Yang, R. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.07.030 · Cited by 102 · see citing works

Impact of HIV on CD8+ T Cell CD57 Expression Is Distinct from That of CMV and Aging

Lee, S. A., Sinclair, E., Hatano, H., Hsue, P. Y., Epling, L., Hecht, F. M., Bangsberg, D. R., Martin, J. N., McCune, J. M., Deeks, S. G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089444 · Cited by 102 · see citing works

Induction of Cytotoxic T Lymphocyte Antigen 4 (Ctla-4) <u>Restricts</u> Clonal Expansion of Helper T Cells

Doyle, A. M., Mullen, A. C., Villarino, A. V., Hutchins, A. S., High, F. A., Lee, H. W., Thompson, C. B., & Reiner, S. L. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.7.893 · Cited by 102 · see citing works

Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen

Sebo, T. J., Cheville, J. C., Riehle, D., Lohse, C. M., Pankratz, V. S., Myers, R. P., Blute, M. L., & Zincke, H. (2001) · Cancer · doi:10.1002/1097-0142(20010601)91:11 · Cited by 100 · see citing works

Impaired antigen-induced CD8+ T cell clonal expansion in aging is due to defects in antigen presenting cell function

Plowden, J., Renshaw-Hoelscher, M., Gangappa, S., Engleman, C., Katz, J. M., & Sambhara, S. (2004) · Cellular Immunology · doi:10.1016/j.cellimm.2004.07.001 · Cited by 98 · see citing works

Effects of aging on early B‐ and T‐cell development

Min, H., Montecino‐Rodriguez, E., & Dorshkind, K. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00263.x · Cited by 96 · see citing works

Enumeration of human peripheral blood dendritic cells throughout the life

Orsini, G., Legitimo, A., Failli, A., Massei, F., Biver, P., & Consolini, R. (2012) · International Immunology · doi:10.1093/intimm/dxs006 · Cited by 91 · see citing works

Influenza-Induced Production of Interferon-Alpha is Defective in Geriatric Individuals

Canaday, D. H., Amponsah, N. A., Jones, L., Tisch, D. J., Hornick, T. R., & Ramachandra, L. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9374-9 · Cited by 89 · see citing works

The frequency of regulatory CD3+CD8+CD28−CD25+ T lymphocytes in human peripheral blood increases with age

Simone, R., Zicca, A., & Saverino, D. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0907627 · Cited by 86 · see citing works

Ageing, autoimmunity and arthritis: Perturbations of TCR signal transduction pathways with ageing – a biochemical paradigm for the ageing immune system

Fülöp, T., Larbi, A., Dupuis, G., & Pawelec, G. (2003) · Arthritis Research & Therapy · doi:10.1186/ar1019 · Cited by 81 · see citing works

Impaired secretion of interferons by dendritic cells from aged subjects to influenza

Prakash, S., Agrawal, S., Cao, J., Gupta, S., & Agrawal, A. (2012) · AGE · doi:10.1007/s11357-012-9477-8 · Cited by 80 · see citing works

Reduced numbers of plasmacytoid dendritic cells in aged blood donors

Pérez-Cabezas, B., Naranjo-Gómez, M., Fernández, M. A., Grífols, J. R., Pujol-Borrell, R., & Borràs, F. E. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2007.05.010 · Cited by 80 · see citing works

Costimulatory mechanisms in the elderly

Effros, R. B. (2000) · Vaccine · doi:10.1016/s0264-410x(99)00503-4 · Cited by 79 · see citing works

Can exercise-related improvements in immunity influence cancer prevention and prognosis in the elderly?

Bigley, A. B., Spielmann, G., LaVoy, E. C. P., & Simpson, R. J. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.06.010 · Cited by 75 · see citing works

Age‐related alterations of gene expression patterns in human CD8⁺ T cells

Cao, J., Gollapudi, S., Sharman, E. H., Jia, Z., & Gupta, S. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2009.00534.x · Cited by 71 · see citing works

The aging bone marrow and its impact on immune responses in old age

Pritz, T., Weinberger, B., & Grubeck‐Loebenstein, B. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.06.016 · Cited by 71 · see citing works

Increased tumor-infiltrating CD8+Foxp3+ T lymphocytes are associated with tumor progression in human gastric cancer

Peng, L., Zhuang, Y., Shi, Y., Zhao, Y., Wang, T., Chen, N., Cheng, P., Liu, T., Liu, X.-F., Zhang, J., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1277-6 · Cited by 60 · see citing works

Adenosine Deaminase Modulation of Telomerase Activity and Replicative Senescence in Human CD8 T Lymphocytes

Parish, S. T., Kim, S., Sekhon, R. K., Wu, J. E., Kawakatsu, Y., & Effros, R. B. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903647 · Cited by 59 · see citing works

Immune checkpoint inhibitors in older adults

Elias, R., Morales, J., Rehman, Y., & Khurshid, H. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0534-9 · Cited by 59 · see citing works

CD95-mediated apoptosis in naïve, central and effector memory subsets of CD4+ and CD8+ T cells in aged humans.

Gupta, S., & Gollapudi, S. (2008) · Experimental Gerontology · doi:10.1016/j.exger.2007.12.006 · Cited by 57 · see citing works

As we age: Does slippage of quality control in the immune system lead to collateral damage?

Müller, L., & Pawelec, G. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.01.005 · Cited by 52 · see citing works

Plasmacytoid dendritic cells and their Toll-like receptor 9 expression selectively decrease with age

Garbe, K., Bratke, K., Wagner, S., Virchow, J. C., Jr., & Lommatzsch, M. (2012) · Human Immunology · doi:10.1016/j.humimm.2012.02.007 · Cited by 49 · see citing works

Naïve and memory CD8 T cell pool homeostasis in advanced aging: impact of age and of antigen-specific responses to cytomegalovirus

Vescovini, R., Fagnoni, F. F., Telera, A. R., Bucci, L., Pedrazzoni, M., Magalini, F., Stella, A., Pasin, F., Medici, M. C., Calderaro, A., et al. (2014) · AGE · doi:10.1007/s11357-013-9594-z · Cited by 48 · see citing works

Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+).

Friedman, C. F., Horvat, T. Z., Minehart, J. C., Panageas, K. S., Callahan, M. K., Chapman, P. B., Momtaz, P., Postow, M. A., Shoushtari, A. N., Wolchok, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.10009 · Cited by 47 · see citing works

Aging-associated subpopulations of human CD8+ T-lymphocytes identified by their CD28 and CD57 phenotypes

Onyema, O. O., Njemini, R., Forti, L. N., Bautmans, I., Aerts, J. L., Waele, M. D., & Mets, T. F. (2015) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2015.08.007 · Cited by 45 · see citing works

Immunomodulatory role of high-density lipoproteins: impact on immunosenescence

Larbi, A., Fortin, C. F., Dupuis, G., Berrougui, H., Khalil, A., & Fülöp, T. (2014) · AGE · doi:10.1007/s11357-014-9712-6 · Cited by 44 · see citing works

Dysfunction of dendritic cells in aged C57BL/6 mice leads to failure of natural killer cell activation and of tumor eradication

Guo, Z., Tilburgs, T., Wong, B., & Strominger, J. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414780111 · Cited by 40 · see citing works

Tumor-Infiltrating Dendritic Cells May Be Used as Clinicopathologic Prognostic Factors in Endometrial Carcinoma

Lijun, Z., Xin, Z., Danhua, S., Li, X., Wang, J., Huilan, W., & Lihui, W. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31825401c6 · Cited by 38 · see citing works

Decline of T cell-related immune functions in cancer patients and an attempt to restore them through infusion of activated autologous T cells

Hirokawa, K., Utsuyama, M., Ishikawa, T., Kikuchi, Y., Kitagawa, M., Fujii, Y., Hideo, N., Uetake, H., & Sugihara, K. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2008.05.001 · Cited by 34 · see citing works

A population biological approach to understanding the maintenance and loss of the T‐cell repertoire during aging

Johnson, P. L. F., Goronzy, J. J., & Antia, R. (2014) · Immunology · doi:10.1111/imm.12244 · Cited by 34 · see citing works

Is there a clinical benefit of anti-PD-1 in patients older than 75 years with previously treated solid tumour?

Landre, T., Taleb, C., Nicolas, P., & Guetz, G. D. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3070 · Cited by 32 · see citing works

Are macrophages, myeloid derived suppressor cells and neutrophils mediators of local suppression in healthy and cancerous tissues in aging hosts?

Jackaman, C., & Nelson, D. J. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.11.009 · Cited by 31 · see citing works

Gene expression and generation of CD28−CD8 T cells mediated by interleukin 15

Godlove, J. M., CHIU, W., & Weng, N. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2006.11.015 · Cited by 28 · see citing works

Immunosenescence in the nursing home elderly

Johnstone, J., Millar, J., Lelic, A., Verschoor, C. P., Walter, S. D., Devereaux, P. J., Bramson, J. L., & Loeb, M. B. (2014) · BMC Geriatrics · doi:10.1186/1471-2318-14-50 · Cited by 27 · see citing works

Myeloid-derived suppressor cells promote age-related increase of lung cancer growth via B7-H1

Chen, S., Liu, H., Su, N., Zhang, G., & Wang, L. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.12.001 · Cited by 23 · see citing works

Differences in TCR-Vβ Repertoire and Effector Phenotype between Tumor Infiltrating Lymphocytes and Peripheral Blood Lymphocytes Increase with Age

Shao, H., Ou, Y., Wang, T., Shen, H., Wu, F., Zhang, W., Tao, C., Yin, Y., Bo, H., Wang, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102327 · Cited by 18 · see citing works

Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study

Melero, I., Sangro, B., Yau, T. C. C., Hsu, C., Kudo, M., Crocenzi, T. S., Kim, T.-Y., Choo, S. P., Trojan, J., Meyer, T., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw371.07 · Cited by 5 · see citing works

219O Safety and preliminary efficacy of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of the phase 1/2 CheckMate-040 study

Melero, I., Sangro, B., Yau, T. O., Hsu, C.-H., Kudo, M., Crocenzi, T. S., Kim, T.-Y., Choo, S. P., Trojan, J., Meyer, T., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw582 · Cited by 4 · see citing works

Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes?

Fulop, T., Larbi, A., Dupuis, G., Le Page, A., Frost, E. H., Cohen, A. A., Witkowski, J. M., & Franceschi, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01960 · Cited by 1,364 · see citing works

How the ageing microenvironment influences tumour progression

Fane, M., & Weeraratna, A. T. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0222-9 · Cited by 849 · see citing works

Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention

Aiello, A., Farzaneh, F., Candore, G., Caruso, C., Davinelli, S., Gambino, C. M., Ligotti, M. E., Zareian, N., & Accardi, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02247 · Cited by 693 · see citing works

The integration of inflammaging in age-related diseases

Fülöp, T., Witkowski, J. M., Olivieri, F., & Larbi, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.09.003 · Cited by 356 · see citing works

Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies

Nosaki, K., Saka, H., Hosomi, Y., Baas, P., de Castro, G., Reck, M., Wu, Y.-L. L. C., Brahmer, J. R., Felip, E., Sawada, T., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.07.004 · Cited by 284 · see citing works

Cancer and Aging: Two Tightly Interconnected Biological Processes

Berben, L., Floris, G., Wildiers, H. P. M. W., & Hatse, S. (2021) · Cancers · doi:10.3390/cancers13061400 · Cited by 241 · see citing works

Efficacy of PD-1 &amp; PD-L1 inhibitors in older adults: a meta-analysis

Elias, R., Giobbie-Hurder, A., McCleary, N. J., Ott, P., Hodi, F. S., & Rahma, O. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0336-8 · Cited by 218 · see citing works

Immune checkpoint inhibitors and elderly people: A review

Daste, A., Domblides, C., Gross‐Goupil, M., Chakiba, C., Quivy, A., Cochin, V., de Monès, E., Larmonier, N., Soubeyran, P., & Ravaud, A. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.044 · Cited by 189 · see citing works

Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly

Pereira, B. I., Xu, X., & Akbar, A. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583019 · Cited by 182 · see citing works

Immune Checkpoint Inhibitors in Real‐World Treatment of Older Adults with Non–Small Cell Lung Cancer

Muchnik, E., Loh, K. P., Strawderman, M. S., Magnuson, A. M., Mohile, S. G., Estrah, V., & Maggiore, R. J. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15750 · Cited by 116 · see citing works

Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer

van Holstein, Y., Kapiteijn, E., Bastiaannet, E., van den Bos, F., Portielje, J. E. A., & de Glas, N. A. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00697-2 · Cited by 114 · see citing works

Targeting immunosenescence and inflammaging: advancing longevity research

Nguyen, T. Q. T., & Cho, K. A. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01527-9 · Cited by 94 · see citing works

Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson’s Disease

Kuštrimović, N. Z., Marino, F., & Cosentino, M. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181009161048 · Cited by 74 · see citing works

The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study

Karantanos, T., Karanika, S., Seth, B., & Gignac, G. A. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1908-2 · Cited by 72 · see citing works

Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age

Saba, N. F., Blumenschein, G. R., Guigay, J., Licitra, L. F., Fayette, J., Harrington, K. J., Kiyota, N., Gillison, M. L., Ferris, R. L., Jayaprakash, V., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.06.017 · Cited by 68 · see citing works

Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications

Zhao, B., Wu, B. C., Feng, N., Zhang, X., Zhang, X., Wei, Y., & Zhang, W. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01426-4 · Cited by 65 · see citing works

Clinical perspectives on the age-related increase of immunosuppressive activity

Salminen, A. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02193-4 · Cited by 57 · see citing works

Immunotherapy in older patients with cancer

Granier, C., Gey, A., Roncelin, S., Weiss, L., Paillaud, É., & Tartour, É. (2020) · Biomedical Journal · doi:10.1016/j.bj.2020.07.009 · Cited by 56 · see citing works

Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice

Zhang, C., Lei, L., Yang, X., Ma, K., Zheng, H., Su, Y., Jiao, A., Wang, X., Liu, H., Zou, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002809 · Cited by 48 · see citing works

The use of immunotherapy in older patients with advanced non-small cell lung cancer

Tagliamento, M., Frélaut, M., Baldini, C., Naigeon, M., Nencioni, A., Chaput, N., & Besse, B. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102394 · Cited by 47 · see citing works

Innate Immunity and Influenza A Virus Pathogenesis: Lessons for COVID-19

Hartshorn, K. L. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.563850 · Cited by 44 · see citing works

Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Yan, X., Tian, X., Wu, Z., & Han, W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01671 · Cited by 45 · see citing works

Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients

Perrotta, F., Rocco, D., Vitiello, F., Palma, R. D., Guerra, G., Luca, A. D., Navani, N., & Bianco, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092258 · Cited by 43 · see citing works

Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study

Ridolfi, L., Rosa, F. D., Petracci, E., Tanda, E. T., Marra, E., Pigozzo, J., Marconcini, R., Guida, M., Cappellini, G. C. A., Gallizzi, G., et al. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.12.012 · Cited by 40 · see citing works

CD48 is a key molecule of immunomodulation affecting prognosis in glioma

Zou, C., Zhu, C. Y., Guan, G., Guo, Q., Liu, T., Shen, S., Yan, Z., Xu, X., Lin, Z., Chen, L., et al. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s198762 · Cited by 36 · see citing works

Management of immunotherapy toxicities in older adults

Bhandari, S., Gill, A. S., Perez, C. A., & Jain, D. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.09.001 · Cited by 31 · see citing works

Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies

Zhao, L.-P., Hu, J.-H., Hu, D., Wang, H., Huang, C.-G., Luo, R., Huang, X., Huang, X., Xie, T., & Lou, J.-S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112949 · Cited by 32 · see citing works

Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis

Huo, G., Liu, W., & Chen, P. (2023) · BMC Cancer · doi:10.1186/s12885-023-10605-y · Cited by 30 · see citing works

Patient Selection for Anti-PD-1/PD-L1 Therapy in Advanced Non-Small-Cell Lung Cancer: Implications for Clinical Practice

Califano, R., Lal, R., Lewanski, C. R., Nicolson, M. C., Ottensmeier, C. H. H., Popat, S., Hodgson, M. J., & Postmus, P. E. (2018) · Future Oncology · doi:10.2217/fon-2018-0330 · Cited by 30 · see citing works

Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis

Zhang, L., Sun, L., Yu, J., Shan, F., Zhang, K., Pang, X., Ma, C., Zhang, Y., Shen, M., Ma, S., et al. (2019) · BioMed Research International · doi:10.1155/2019/9853701 · Cited by 30 · see citing works

Efficacy of Anti-PD-1/PD-L1 Monotherapy or Combinational Therapy in Patients Aged 75 Years or Older: A Study-Level Meta-Analysis

Nie, R., Chen, G.-M., Wang, Y., Zhou, J., Duan, J., Zhou, Z., & Yuan, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.538174 · Cited by 30 · see citing works

Age Associated Microbiome and Microbial Metabolites Modulation and Its Association With Systemic Inflammation in a Rhesus Macaque Model

Pallikkuth, S., Méndez, R., Russell, K. B., Sirupangi, T., Kvistad, D., Pahwa, R., Villinger, F. J., Banerjee, S., & Pahwa, S. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.748397 · Cited by 30 · see citing works

The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis

Li, P., Yang, X., Feng, Y., Wu, L., Ma, W., Ding, G., Wei, Y., & Sun, L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s165368 · Cited by 29 · see citing works

Endometrial cancer in the elderly: Characteristics, prognostic and risk factors, and treatment options

Forte, M., Cecere, S. C., Napoli, M. D., Ventriglia, J., Tambaro, R., Rossetti, S., Passarelli, A. M., Casartelli, C., Rauso, M., Alberico, G., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104533 · Cited by 29 · see citing works

The effectiveness of PD-1 inhibitors in non-small cell lung cancer (NSCLC) patients of different ages

Wu, Y. C., Ju, Q., Qian, B., Zhang, F., & Shi, H. M. (2017) · Oncotarget · doi:10.18632/oncotarget.23678 · Cited by 29 · see citing works

Immunotherapy in older patients with hepatocellular carcinoma

Lyu, N., Yi, J., & Zhao, M. D. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.024 · Cited by 29 · see citing works

Effect of age and sex on immune checkpoint expression and kinetics in human T cells

Reitsema, R. D., Cadena, R. H., Nijhof, S., Abdulahad, W. H., Huitema, M. G., Paap, D., Brouwer, E., Boots, A. M. H., & Heeringa, P. (2020) · Immunity & Ageing · doi:10.1186/s12979-020-00203-y · Cited by 28 · see citing works

Efficacy and safety of immune checkpoint inhibitors in elderly patients with advanced non-small cell lung cancer: a systematic review and meta-analysis

Yao, J., Li, S., Bai, L., Chen, J., Ren, C., Liu, T., Qiu, J., & Dang, J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103081 · Cited by 28 · see citing works

Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics

Liu, W., Huo, G., & Chen, P. (2023) · BMC Cancer · doi:10.1186/s12885-023-10959-3 · Cited by 25 · see citing works

Toxicity in Older Patients with Cancer Receiving Immunotherapy: An Observational Study

Hoi, E. T. V., Trompet, S., van Holstein, Y., van den Bos, F., van Heemst, D., Codrington, H., Labots, G., Lohman, S., Özkan, A., Portielje, J. E. A., et al. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01114-z · Cited by 24 · see citing works

Targeting immunosenescence for improved tumor immunotherapy

Liu, Z., Zuo, L., Zhou, Z., Liu, S., Ba, Y., Zuo, A., Ren, Y., Zhang, C., Chen, Y., Ma, H., et al. (2024) · MedComm · doi:10.1002/mco2.777 · Cited by 24 · see citing works

Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer

Sabatier, R., Nicolas, E., Paciencia, M., Jonville‐Béra, A. ‐., Madroszyk, A., Cécile, M., Braticevic, C., Duran, S., Tassy, L., Rouby, F., et al. (2018) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2018.02.011 · Cited by 24 · see citing works

The Role of Immunosenescence in Cerebral Small Vessel Disease: A Review

Cuore, A. D., Pacinella, G., Riolo, R., & Tuttolomondo, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137136 · Cited by 25 · see citing works

Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy

Mancuso, S., Mattana, M., Carlisi, M., Santoro, M., & Siragusa, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063368 · Cited by 27 · see citing works

Overcoming Barriers of Age to Enhance Efficacy of Cancer Immunotherapy: The Clout of the Extracellular Matrix

Owyong, M., Efe, G., Owyong, M., Abbasi, A. J., Sitarama, V., & Plaks, V. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00019 · Cited by 23 · see citing works

Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients

Kasanen, H. H. E., Hernberg, M., Mäkelä, S., Brück, O. E., Juteau, S., Kohtamäki, L. M., Ilander, M. M., Mustjoki, S. M., & Kreutzman, A. S. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02497-9 · Cited by 22 · see citing works

Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer

Zhang, S., Pease, D. F., Kulkarni, A. A., Kumar, M., Shanley, R., Xu, B., Joshi, S. P., & Patel, M. R. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/11795549211004489 · Cited by 22 · see citing works

Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults

Elias, R., Morales, J. K., & Presley, C. J. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0619-0 · Cited by 22 · see citing works

Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma

Leroy, V., Gerard, É., Dutriaux, C., Prey, S., Gey, A., Mertens, C., Beylot-Barry, M., & Pham‐Ledard, A. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02298-9 · Cited by 22 · see citing works

Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies

Sakakida, T., Ishikawa, T., Uchino, J., Tabuchi, Y., Komori, S., Asai, J., Arai, A., Tsunezuka, H., Kosuga, T., Konishi, H., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11875 · Cited by 21 · see citing works

Cancer Prevention and Treatment by Wholistic Nutrition.

Campbell, T. C. (2017) · PubMed · Cited by 20 · see citing works

Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study

Kleemann, J., Jäger, M., Valesky, E. M., Kippenberger, S., Kaufmann, R., & Meißner, M. (2021) · Cancer Management and Research · doi:10.2147/cmar.s286917 · Cited by 19 · see citing works

Immunotherapy in Older Adults: A Checkpoint to Palliation?

Elias, R., & Odejide, O. O. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238795 · Cited by 19 · see citing works

Safety and Effectiveness of Immune Checkpoint Inhibitors in Older Patients with Cancer: A Systematic Review of 48 Real-World Studies

Luciani, A., Ghidini, A., Dottorini, L., & Petrelli, F. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00899-7 · Cited by 19 · see citing works

The Epithelial–Mesenchymal Transition Influences the Resistance of Oral Squamous Cell Carcinoma to Monoclonal Antibodies via Its Effect on Energy Homeostasis and the Tumor Microenvironment

Bai, Y., Sha, J., Okui, T., Moriyama, I., Ngo, H. X., Tatsumi, H., & Kanno, T. (2021) · Cancers · doi:10.3390/cancers13235905 · Cited by 18 · see citing works

Treatment of Urothelial Cancer in Elderly Patients: Focus on Immune Checkpoint Inhibitors

Jodon, G., Fischer, S. M., & Kessler, E. R. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0540-8 · Cited by 17 · see citing works

The Aging-Related Prognostic Signature Reveals the Landscape of the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma

Chen, F., Gong, X., Meng, X., Feng, Y., Wu, J., Yu, C., & Li, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.857994 · Cited by 17 · see citing works

Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis

Deng, R., Zhang, H., Li, Y., & Shi, Y. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000442 · Cited by 17 · see citing works

Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer

Yang, Z., Chen, Y., Wang, Y., Hu, M., Qian, F., Zhang, Y., Zhang, B., Zhang, W., & Han, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.807575 · Cited by 17 · see citing works

Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy

Pradeep, J., Win, T. T., Aye, S. N., & Sreeramareddy, C. T. (2022) · Journal of Cancer · doi:10.7150/jca.72210 · Cited by 16 · see citing works

Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study

Bassanelli, M., Ricciuti, B., Giannarelli, D., Cecere, F. L., Roberto, M., Giacinti, S., Barucca, V., Santarelli, M., Ruggeri, E. M., Marchetti, P., et al. (2021) · Tumori Journal · doi:10.1177/03008916211004733 · Cited by 16 · see citing works

Considerations and Challenges in the Management of the Older Patients with Gastric Cancer

Loizides, S., & Papamichael, D. (2022) · Cancers · doi:10.3390/cancers14061587 · Cited by 16 · see citing works

The impact of smoking on the effectiveness of immune checkpoint inhibitors — a systematic review and meta-analysis

Lee, K., Lord, S. J., Kasherman, L., Marschner, I. C., Stockler, M. R., Gralla, R. J., Yang, J. C., Mok, T. S. K., & Lee, C. K. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1670354 · Cited by 16 · see citing works

Inhibitory Immune Checkpoint Molecule Expression in Clinical Sepsis Studies: A Systematic Review

Busch, L. M., Sun, J., Eichacker, P. Q., & Torabi‐Parizi, P. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004496 · Cited by 15 · see citing works

Drug-eluting beads bronchial arterial chemoembolization/bronchial arterial infusion chemotherapy with and without PD-1 blockade for advanced non-small cell lung cancer: a comparative single-center cohort study

Xu, S., Li, Y., Bie, Z., & Li, X. (2023) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-23-287 · Cited by 15 · see citing works

Immunotherapy in Older Patients with Cancer: A Narrative Review

Smith, A., Boby, J. M., Benny, S. J., Ghazali, N., Vermeulen, E. T., & George, M. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s435001 · Cited by 15 · see citing works

Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma

Zhao, B., Zhao, H., & Zhao, J. (2018) · International Journal of Cancer · doi:10.1002/ijc.31813 · Cited by 15 · see citing works

Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient?

Al‐Mansour, Z., Pang, L., & Bathini, V. G. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0619-2 · Cited by 15 · see citing works

Age-related efficacy of immunotherapies in advanced non-small cell lung cancer: a comprehensive meta-analysis

Ding, Y., Lei, S., Wang, L., Tang, L., Zhang, Y., Liao, Y., Deng, X., Li, Y., Gong, Y., & Li, Y. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107925 · Cited by 14 · see citing works

Efficacy of immune checkpoint inhibitors in elderly patients aged ≥ 75 years

Petrelli, F., Inno, A., Ghidini, A., Gori, S., & Bersanelli, M. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02779-2 · Cited by 15 · see citing works

Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry

Jochems, A., Bastiaannet, E., Aarts, M. J. B., van Akkooi, A. C. J., van den Berkmortel, F. W. P. J., Boers‐Sonderen, M. J., van den Eertwegh, A. J. M., de Glas, N. A., de Groot, J. W. B., Haanen, J. B. A. G., et al. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.04.006 · Cited by 14 · see citing works

Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature

de la Fouchardière, C., Decoster, L., Samalin, E., Terret, C., Kenis, C., Droz, J., Coutzac, C., & Smyth, E. C. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102289 · Cited by 13 · see citing works

Efficacy of Immune Checkpoint Inhibitors in Cancer Patients of Different Ages: A Meta-Analysis

Li, J., & Gu, J. H. (2019) · Future Oncology · doi:10.2217/fon-2019-0279 · Cited by 13 · see citing works

Efficacy and safety profile of avelumab monotherapy

Zhao, B., Gao, M., Zhao, H., Zhao, J., & Shen, X. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103464 · Cited by 12 · see citing works

Immunosenescence and immunotherapy in older NSCLC patients

Zhang, J., Zhao, L., Li, H., Jia, Y., & Kong, F. (2024) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1523_23 · Cited by 12 · see citing works

Immunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma

Zhang, D., Zhu, Y., Shen, Z., Ma, S., Liu, S., & Lu, Z. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.02.010 · Cited by 12 · see citing works

Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD‐1/PD‐L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta‐Analysis

Wei, Y., Li, Y., Du, Q., Peng, X., Jin, J., Guo, H. Y., Li, Y., & Li, Q. (2020) · Journal of Immunology Research · doi:10.1155/2020/5269787 · Cited by 11 · see citing works

Single cell–resolved cellular, transcriptional, and epigenetic changes in mouse T cell populations linked to age-associated immune decline

He, J., Burova, E., Taduriyasas, C., Ni, M., Adler, C., Wei, Y., Negron, N., Xiong, K., Bai, Y., Shavlakadze, T., et al. (2025) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.2425992122 · Cited by 9 · see citing works

Polymorbidity, ageing of immune system and low-grade systemic inflammation: a challenge for modern medicine

Shirinsky, V. S., & Shirinsky, I. V. (2020) · Medical Immunology (Russia) · doi:10.15789/1563-0625-pao-2042 · Cited by 12 · see citing works

Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers

Li, M., Kaili, D., & Shi, L. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i1.19 · Cited by 11 · see citing works

The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer

Spagnuolo, A., & Gridelli, C. (2023) · Cancers · doi:10.3390/cancers15082319 · Cited by 12 · see citing works

Disparity in Outcomes of Melanoma Adjuvant Immunotherapy by Demographic Profile

Ikeguchi, A. P., Machiorlatti, M. G., & Vesely, S. K. (2020) · Melanoma Management · doi:10.2217/mmt-2020-0002 · Cited by 10 · see citing works

Real-life safety of PD-1 and PD-L1 inhibitors in older patients with cancer: An observational study

Storm, B. N., Kalkhoran, H. A., Wilms, E. B., Brocken, P., Codrington, H., Houtsma, D., Portielje, J. E. A., de Glas, N. A., van der Ziel, D., van den Bos, F., et al. (2022) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2022.05.013 · Cited by 10 · see citing works

Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response

Carey, A. E., & Weeraratna, A. T. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108698 · Cited by 9 · see citing works

Financial Toxicity: Management as an Adverse Effect of Cancer Treatment

Fessele, K. L. (2017) · Clinical journal of oncology nursing · doi:10.1188/17.cjon.762-764 · Cited by 9 · see citing works

Pooled analysis of nivolumab treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the United States and Germany

Singh, P., McDonald, L., Waldenberger, D., Welslau, M., von der Heyde, E., Gauler, T. C., & Dietz, A. (2021) · Head & Neck · doi:10.1002/hed.26853 · Cited by 9 · see citing works

Identification of Aging‐Related Genes Associated with Prognostic Value and Immune Microenvironment Characteristics in Diffuse Large B‐Cell Lymphoma

Luo, C., Nie, H., & Yu, L. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/3334522 · Cited by 9 · see citing works

Immune checkpoint inhibitor toxicity and associated outcomes in older patients with cancer

Hayashi‐Tanner, Y., Polewski, P. J., Gaddam, M., Fisher, N. R., Kovacs, A. J., & Marinier, D. E. (2022) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2022.05.007 · Cited by 9 · see citing works

Association of Increased Age With Decreased Response to Intravesical Instillation of Bacille Calmette-Guérin in Patients With High-Risk Non-Muscle Invasive Bladder Cancer: Retrospective Multi-Institute Results From the Japanese Urological Oncology Research Group JUOG-UC-1901-BCG

Inoue, T., Miyake, M., Nishimura, N., Onozawa, M., Kashima, S., Numakura, K., Narita, S., Iida, K., Uemura, M., Matsushita, Y., et al. (2022) · Urology · doi:10.1016/j.urology.2022.05.034 · Cited by 9 · see citing works

T-cell senescence: Unlocking the tumor immune “Dark Box” - A multidimensional analysis from mechanism to tumor immunotherapeutic intervention

Cheng, J., Zheng, J., Ma, C., Li, Y., & Hao, H. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.05.010 · Cited by 8 · see citing works

Immune Checkpoint Inhibitors in the Treatment of Advanced Melanoma in Older Patients: An Overview of Published Data

Lens, M. B., & Schachter, J. (2025) · Cancers · doi:10.3390/cancers17111835 · Cited by 8 · see citing works

Efficacy of PD-1/PD-L1 Plus CTLA-4 Inhibitors in Solid Tumors Based on Clinical Characteristics: a Meta-Analysis

Huo, G., Liu, W., Zhang, S., & Chen, P. (2023) · Immunotherapy · doi:10.2217/imt-2022-0140 · Cited by 8 · see citing works

Steroidogenic acute regulatory protein mediated variations of gender-specific sex neurosteroids in Alzheimer’s disease: Relevance to hormonal and neuronal imbalance

Manna, P. R., Yang, S., Manna, C., Waters, H., Islam, M. A., Reddy, A. P., Rawat, P., & Reddy, P. H. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105969 · Cited by 7 · see citing works

Targeting Aging Hallmarks with Monoclonal Antibodies: A New Era in Cancer Immunotherapy and Geriatric Medicine

Bo, M. D., Gambirasi, M., Vruzhaj, I., Cecchin, E., Pishdadian, A., Toffoli, G., & Safa, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26114982 · Cited by 7 · see citing works

Blood based immune biomarkers associated with clinical frailty scale in older patients with melanoma receiving checkpoint inhibitor immunotherapy

Hoi, E. T. V., Santegoets, S. J. A. M., Mooijaart, S. P., van Heemst, D., Özkan, A., Verdegaal, E. M. E., Slingerland, M., Kapiteijn, E., van der Burg, S. H., Portielje, J. E. A., et al. (2024) · Immunity & Ageing · doi:10.1186/s12979-024-00463-y · Cited by 7 · see citing works

Personal and clinical characteristics associated with immunotherapy effectiveness in stage IV non-small cell lung cancer

Patel, K. H., Alpert, N., Tuminello, S., & Taioli, E. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-682 · Cited by 7 · see citing works

Evaluating the potential of immunotherapy and chemoimmunotherapy in the treatment of elderly non-small cell lung cancer patients: A real-world study

Endo, S., Honda, T., Sato, K., Kubota, N., Kamoshida, T., Mochizuki, A., Fujii, M., Ochi, J., Miyazaki, Y., & Tsukada, Y. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100755 · Cited by 7 · see citing works

Nanoparticle-mediated delivery of herbal-derived natural products to modulate immunosenescence-induced drug resistance in cancer therapy: a comprehensive review

Yang, L., Wu, W. D., Yang, J., & Xu, M. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1567896 · Cited by 7 · see citing works

Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?

Wu, Q., Luo, S., & Xie, X. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000426 · Cited by 6 · see citing works

Efficacy of Pd-1/Pd-L1 Inhibitors in Advanced Gastroesophageal Cancer Based on Characteristics: A Meta-Analysis

Liu, W., Huo, G., & Chen, P. (2023) · Immunotherapy · doi:10.2217/imt-2022-0305 · Cited by 6 · see citing works

Immune Checkpoint Inhibitors in Geriatric Oncology

Cook, S. L., Amin, M. A., Bari, S., Poonnen, P. J., Khasraw, M., & Johnson, M. O. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01528-3 · Cited by 18 · see citing works

Clinical benefit of immune checkpoint inhibitors in elderly cancer patients: Current evidence from immunosenescence pathophysiology to clinical trial results

Ziogas, D. C., Theocharopoulos, C., Aravantinou-Fatorou, K., Boukouris, A. E., Stefanou, D. T., Anastasopoulou, A. N., Lialios, P., Lyrarakis, G., & Gogas, H. J. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104635 · Cited by 19 · see citing works

Aging, immune senescence, and immunotherapy: a comprehensive review

Elias, R., Hartshorn, K., Rahma, O., Lin, N., & Snyder-Cappione, J. E. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.08.006 · Cited by 96 · see citing works

Immunotherapy in older adults with gynecologic cancers: rethinking age as a limiting factor

Yoshida, Y., Orisaka, M., Inoue, D., & Sasaki, H. (2025) · Figshare · doi:10.6084/m9.figshare.29923961

Impact of immunosenescence and inflammaging on the effects of immune checkpoint inhibitors

Hou, C., Wang, Z., & Lu, X. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.08.001 · Cited by 37 · see citing works